Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase – Here’s Why

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) shares saw an uptick in trading volume on Wednesday . 53,166,030 shares were traded during mid-day trading, an increase of 1,672% from the previous session’s volume of 3,000,232 shares.The stock last traded at $52.7150 and had previously closed at $50.00.

Key Terns Pharmaceuticals News

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to acquire Terns for $53.00 per share in cash, valuing the company at about $6.7 billion; the deal highlights the value of Terns’ lead oncology asset (TERN-701) and explains the upward stock move as investors price in the buyout and closing timeline (expected Q2 2026, tender offer subject to customary conditions). Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers
• Positive Sentiment: Deal rationale: analysts and coverage note Merck is bolstering its oncology/CML pipeline ahead of Keytruda patent pressures; the strategic fit supports the takeover premium and long-term value for Terns’ program. Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
• Neutral Sentiment: Several brokerages have reiterated neutral/hold/market-perform ratings with price targets essentially in line with the $53 deal price (HC Wainwright and TD Cowen noted $53 PTs), indicating limited upside to the cash offer but signaling analyst comfort with the transaction valuation. HC Wainwright Reaffirms Neutral Rating for Terns Pharmaceuticals (NASDAQ:TERN)
• Neutral Sentiment: Terns has traded up to a new 52‑week high on the deal news; the stock is effectively trading at the announced cash price while the tender offer and customary closing conditions remain the key near‑term catalysts. Terns Pharmaceuticals (NASDAQ:TERN) Hits New 52-Week High – Still a Buy?
• Negative Sentiment: Multiple shareholder law firms have launched investigations into whether the $53 per‑share price and the sale process are fair to public shareholders; this raises the possibility of litigation, deal delays or renegotiation risk. Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. – TERN
• Negative Sentiment: Ongoing investigations and multiple class‑action notices (other firms including Halper Sadeh, Ademi, Monteverde & Associates) add regulatory/legal overhang that could complicate or slow the closing process and create transaction execution risk. Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TERN. Citizens Jmp restated a “market perform” rating on shares of Terns Pharmaceuticals in a research report on Thursday. Wall Street Zen lowered Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Oppenheimer raised their target price on Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $53.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday. Finally, Truist Financial boosted their price target on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Terns Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $56.90.

Terns Pharmaceuticals Stock Up 0.6%

The firm has a market cap of $5.52 billion, a PE ratio of -51.62 and a beta of -0.31. The business has a 50-day moving average price of $40.96 and a two-hundred day moving average price of $28.74.

Insider Activity

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider owned 50,365 shares of the company’s stock, valued at $1,942,578.05. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at $13,498,068.96. The trade was a 4.80% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 170,409 shares of company stock worth $6,563,769. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Commodore Capital LP purchased a new stake in shares of Terns Pharmaceuticals in the 3rd quarter valued at approximately $42,807,000. Vestal Point Capital LP purchased a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth $181,800,000. Avoro Capital Advisors LLC acquired a new position in shares of Terns Pharmaceuticals during the fourth quarter worth $175,740,000. Janus Henderson Group PLC acquired a new position in shares of Terns Pharmaceuticals during the fourth quarter worth $136,496,000. Finally, Capitolis Liquid Global Markets LLC purchased a new position in Terns Pharmaceuticals in the fourth quarter valued at $123,026,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.